{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:40:34Z","timestamp":1792744834856,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biological Psychiatry Global Open Science"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bpsgos.2026.100806","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:44:49Z","timestamp":1790016289000},"page":"100806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prazosin in the Pharmacologic Management of Alcohol Use Disorder"],"prefix":"10.1016","volume":"6","author":[{"given":"Murray A.","family":"Raskind","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Saxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3333-9735","authenticated-orcid":false,"given":"Tracy L.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpsgos.2026.100806_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1176\/appi.ajp.2021.21030286","article-title":"Medications to treat alcohol use disorder: Targeting the dark side","volume":"178","author":"Mason","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100806_bib2","article-title":"Prazosin-related reductions in daily craving mediates treatment-related daily alcohol use outcomes in alcohol use disorder","volume":"6","author":"Wemm","year":"2026","journal-title":"Biol Psychiatry Glob Open Sci"},{"key":"10.1016\/j.bpsgos.2026.100806_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1176\/appi.ajp.2020.20050609","article-title":"Moderation of prazosin\u2019s efficacy by alcohol withdrawal symptoms","volume":"178","author":"Sinha","year":"2021","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100806_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.alcohol.2007.12.002","article-title":"Alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol","volume":"42","author":"Walker","year":"2008","journal-title":"Alcohol"},{"key":"10.1016\/j.bpsgos.2026.100806_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1530-0277.2008.00829.x","article-title":"The alpha1-adrenergic receptor antagonist, prazosin, reduces alcohol drinking in alcohol-preferring (P) rats","volume":"33","author":"Rasmussen","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.bpsgos.2026.100806_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1530-0277.2008.00807.x","article-title":"A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence","volume":"33","author":"Simpson","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.bpsgos.2026.100806_bib7","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/acer.12703","article-title":"A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder","volume":"39","author":"Simpson","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.bpsgos.2026.100806_bib8","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamainternmed.2020.0249","article-title":"Efficacy of gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: A randomized clinical trial","volume":"180","author":"Anton","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.bpsgos.2026.100806_bib9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.bpsgos.2026.100806_bib10","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1111\/acer.12828","article-title":"Prazosin + naltrexone decreases alcohol drinking more effectively than does either drug alone in P rats with a protracted history of extensive voluntary alcohol drinking, dependence, and multiple withdrawals","volume":"39","author":"Rasmussen","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.bpsgos.2026.100806_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/alcalc\/agae062","article-title":"Naltrexone augmented with prazosin for alcohol use disorder: Results from a randomized controlled proof-of-concept trial","volume":"59","author":"Simpson","year":"2024","journal-title":"Alcohol Alcohol"}],"container-title":["Biological Psychiatry Global Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174326001199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667174326001199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T08:15:46Z","timestamp":1792743346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667174326001199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2667174326001199"],"URL":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100806","relation":{},"ISSN":["2667-1743"],"issn-type":[{"value":"2667-1743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prazosin in the Pharmacologic Management of Alcohol Use Disorder","name":"articletitle","label":"Article Title"},{"value":"Biological Psychiatry Global Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100806","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.bpsgos.2026.100772","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc on behalf of Society of Biological Psychiatry.","name":"copyright","label":"Copyright"}],"article-number":"100806"}}